Fundz

ALX Oncology

South San Francisco, California, United States · Biotechnology, Health Care, Medical

ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing cl

Key facts

Headquarters
South San Francisco, California, United States
Employees
69
Industries
Biotechnology, Health Care, Medical
Status
Public (ALXO)
Website
alxoncology.com
LinkedIn
Company page

Recent activity at ALX Oncology

  • : SEC 8-K (1.01): On October 14, 2026, ALX Oncology Holdings Inc. entered into material exchange agreements with certain stockholders, leading to the surrender of 13,353,384 shares of common stock and the issuance of pre-funded warrants to purchase the same number of shares. Key participants in this transaction included funds affiliated with Blackstone Annex Master Fund L.P., RA Capital Healthcare Fund, L.P., and venBio Global Strategic Fund, L.P. The exchange is set to settle on October 15, 2026, and each pre-funded warrant has an exercise price of $0.001, with specific conditions governing the exercise to limit beneficial ownership percentages. This strategic agreement is expected to enhance the company's capital structure and financial flexibility.
  • : SEC 8-K (5.02): On June 29, 2026, Corey Goodman, Ph.D. resigned as Chairman of the Board and as a member of the Board of ALX Oncology Holdings Inc. for personal reasons, not due to any disagreement with the Company. His resignation was effective at the close of business on the same day. In response to this change, the Board appointed Scott Garland, an independent director, as the new Chairman of the Board also effective June 29, 2026. The Board further restructured its committee compositions which include specific roles assigned to Rekha Hemrajani, Daniel J. Curran, and Chris Takimoto in various committees. This transition is significant for the governance structure of the Company.
  • : SEC 8-K (1.01): On June 25, 2026, ALX Oncology Holdings Inc. entered into a loan and security agreement with HSBC Ventures USA Inc. as the lender and ALX Oncology Inc. as the borrower. This agreement provides a secured term loan facility totaling up to $50 million, with an initial borrowing of $10 million to refinance existing loans and cover closing costs. The loans will mature on June 1, 2030, and are subject to various performance milestones that could unlock additional loan amounts. The transaction is strategically significant for the borrower as it supports ongoing clinical studies and refines financial arrangements. The obligations under the Loan Agreement are secured by the entities' assets and intellectual property, reflecting a commitment to financial stability and growth.
  • : SEC 8-K (5.02): ALX Oncology Holdings Inc. appointed Jeff Knight as Chief Development and Operating Officer effective April 13, 2026. Mr. Knight, aged 55, previously held roles at Crinetics Pharmaceuticals and Poseida Therapeutics, bringing extensive experience in biopharmaceuticals. His appointment involves an annual base salary of $565,000, with a target cash bonus of 40% based on performance. Additionally, he will receive a stock option to purchase 800,000 shares of common stock, vesting over time contingent upon continued service, reflecting a significant strategic hire for the company's operational leadership.
  • : SEC 8-K (1.01): On January 30, 2026, ALX Oncology Holdings Inc. entered into a Material Definitive Agreement with Piper Sandler & Co., UBS Securities LLC, and Wells Fargo Securities, LLC for an underwriting agreement. The Company plans to issue and sell 76,979,112 shares of its common stock at $1.57 per share and pre-funded warrants to purchase 18,574,120 shares at $1.569 each, expecting to raise gross proceeds of approximately $150 million. The offering is scheduled to close on February 2, 2026, subject to customary closing conditions, and includes terms for indemnification and other obligations between the Company and the underwriters. This financing will aid ALX Oncology in advancing its operations and strategic initiatives, with the offering being made under an effective registration statement with the SEC.
  • : SEC 8-K (8.01): On January 30, 2026, ALX Oncology Holdings Inc. announced clinical updates regarding its investigational CD47-inhibitor evorpacept, showing that CD47 expression predicts the activity of this drug in a Phase 1b/2 trial for metastatic breast cancer. The data comes from an exploratory analysis and involves a partnership with Jazz Pharmaceuticals, particularly focusing on the drug ZIIHERA®. In addition, the Company provided preliminary unaudited financial information indicating approximately $48.3 million in cash and investments as of December 31, 2025, which is subject to change upon completion of the financial closing process. This update is significant as it delves into both clinical advancements and vital financial estimates for stakeholders.
  • : SEC 8-K (5.02): On January 21, 2026, ALX Oncology Holdings Inc.'s Board of Directors amended the 2025 Inducement Equity Incentive Plan, increasing the reserved shares for equity awards from 1,300,000 to an aggregate of 2,800,000 shares of common stock. This amendment was executed without stockholder approval as per Nasdaq Listing Rules, allowing incentives for new employees and ensuring compliance with the conditions for inducement awards. The plan includes various equity-based awards reflecting terms similar to the company's 2020 Equity Incentive Plan, particularly regarding changes during a merger or control event. The Inducement Plan is crucial for attracting new talent and fostering company growth.
  • : SEC 8-K (5.02): On January 21, 2026, ALX Oncology Holdings Inc. amended its 2025 Inducement Equity Incentive Plan to increase the number of shares reserved for issuance under the plan by an additional 1,300,000 shares, bringing the total to 2,800,000 shares. This amendment was made effective immediately and did not require stockholder approval in accordance with Nasdaq Listing Rules. The Inducement Plan was originally approved by the Board in January 2025. This increase in available shares is strategic for the company as it allows for more flexibility in granting equity awards to attract and retain talent.
  • : ALX Oncology Appoints Barbara Klencke as Interim Chief Medical Officer
  • : ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer

Leadership

  • Barbara Klencke, Chief Medical Officer
  • Allison Dillon, Chief Business Officer

Verified email and direct lines for ALX Oncology’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.

Employee benefit plans

ALX Oncology files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.

ALX Oncology in the news

Companies similar to ALX Oncology

About ALX Oncology: questions and answers

What does ALX Oncology do?

ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing cl

Where is ALX Oncology headquartered?

ALX Oncology is headquartered in South San Francisco, California, United States.

How many employees does ALX Oncology have?

ALX Oncology has about 69 employees.

What is the latest news on ALX Oncology?

On Oct 14, 2026, SEC 8-K (1.01): On October 14, 2026, ALX Oncology Holdings Inc. entered into material exchange agreements with certain stockholders, leading to the surrender of 13,353,384 shares of common stock and the issuance of pre-funded warrants to purchase the same number of shares. Key participants in this t

Is ALX Oncology a public company?

Yes. ALX Oncology is publicly traded under the ticker ALXO.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches ALX Oncology across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.